|
![](http://e.elijahlistmail.com/db/26589172/243447852/1.gif)
|
Having trouble viewing this email? View it as a Web page. You are receiving this message because you are subscribed to News Releases for National Institutes of Health (NIH).
12/27/2019 02:00 PM EST Findings from NIH-funded study could inform treatment strategies. Update Your E-mail Address | Add Subscriptions | Unsubscribe If you have questions or problems with the subscription service, please contact subscriberhelp.govdelivery.com. For all other inquiries about NIH programs and activities, please contact Ask NIH. Before writing, please view our Frequently Asked Questions page, our Health Information page, or Search our website. This service is provided to you by the National Institutes of Health.
|
![]() | |||||
cannabidiol for epilepsy | |||||
NEWS | |||||
First cannabis drug for epilepsy will be NHS-funded by January 6 The NHS will start prescribing its first cannabis medicine for epilepsy in less than ... Chief executive of the charity Epilepsy Action, Philip Lee, said he was ... Epidyolex is an oral solution containing cannabidiol (CBD), which is legal, ...
| |||||
Childhood Absence Epilepsy Treatment Market Is Set To Experience Revolutionary Growth By 2026 Some doubt a promising drug in the formative years of absence epilepsy treatment market CX-8998 and cannabidiol oral solution. Compliance with ...
| |||||
See more results | Edit this alert |
You have received this email because you have subscribed to Google Alerts. |
![]() |
Send Feedback |
|